CA2082948A1 - Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4 - Google Patents

Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4

Info

Publication number
CA2082948A1
CA2082948A1 CA2082948A CA2082948A CA2082948A1 CA 2082948 A1 CA2082948 A1 CA 2082948A1 CA 2082948 A CA2082948 A CA 2082948A CA 2082948 A CA2082948 A CA 2082948A CA 2082948 A1 CA2082948 A1 CA 2082948A1
Authority
CA
Canada
Prior art keywords
antibodies
relating
receptor binding
immunogenic peptides
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2082948A
Other languages
English (en)
Other versions
CA2082948C (fr
Inventor
Joseph G. Sodroski
William A. Haseltine
Udy Olshevsky
Eirik Helseth
Craig D. Furman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2082948A1 publication Critical patent/CA2082948A1/fr
Application granted granted Critical
Publication of CA2082948C publication Critical patent/CA2082948C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention se rapporte à des peptides immunogènes contenant des résidus d'acides aminés qui définissent un site de liaison avec un récepteur de molécules CD4, à des anticorps dirigés contre ces peptides, à des procédés permettant de réduire la capacité d'une protéine env gp120 à se lier à des molécules CD4, ainsi qu'à des procédés thérapeutiques et prophylactiques utilisant ces anticorps et ces peptides.
CA002082948A 1990-05-16 1991-05-16 Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4 Expired - Fee Related CA2082948C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52463290A 1990-05-16 1990-05-16
US524,632 1990-05-16
US66907291A 1991-03-14 1991-03-14
US669,072 1991-03-14
PCT/US1991/003472 WO1991017764A1 (fr) 1990-05-16 1991-05-16 Peptides immunogenes, anticorps et utilisations de ceux-ci en rapport avec la liaison du recepteur de molecules cd4

Publications (2)

Publication Number Publication Date
CA2082948A1 true CA2082948A1 (fr) 1991-11-17
CA2082948C CA2082948C (fr) 2000-07-11

Family

ID=27061560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002082948A Expired - Fee Related CA2082948C (fr) 1990-05-16 1991-05-16 Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4

Country Status (7)

Country Link
US (2) US5817316A (fr)
EP (1) EP0651818B1 (fr)
JP (1) JPH05507491A (fr)
AT (1) ATE175446T1 (fr)
CA (1) CA2082948C (fr)
DE (1) DE69130741T2 (fr)
WO (1) WO1991017764A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0554401A4 (en) * 1990-10-26 1996-10-30 New York Health Res Inst Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
JPH05262662A (ja) * 1991-07-15 1993-10-12 Calpis Food Ind Co Ltd:The Ｈｉｖ重感染防止剤、抗イディオタイプ抗体作製用抗原及び抗イディオタイプ抗体の製造法
WO1994004574A1 (fr) * 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Immunotherapie du vih
EP0581353A1 (fr) * 1992-07-03 1994-02-02 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Anticorps monoclonaux dirigés contre HIV-1 gp120, lignées cellulaires les produisant et structures epitopiques correspondantes
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6908617B1 (en) 1997-11-10 2005-06-21 Dana-Farber Cancer Institute, Inc. Glycosylated modified primate lentivirus envelope polypeptides
WO1999024464A1 (fr) 1997-11-10 1999-05-20 Dana-Farber Cancer Institute, Inc Polypeptides d'enveloppe de lentivirus de primate, modifies et glycosyles
US6679851B2 (en) * 1998-09-01 2004-01-20 Senorx, Inc. Tissue accessing and anchoring device and method
US7250397B2 (en) * 2000-02-23 2007-07-31 Zealand Pharma A/S Antiarrhythmic peptides
US7585839B2 (en) * 2000-02-23 2009-09-08 Zealand Pharma A/S Medical uses of intercellular communication facilitating compounds
AU2001254567A1 (en) * 2000-05-02 2001-11-12 Simon Fraser University Polypeptides for use as a vaccine and/or treatment for hiv infection
CA2431212A1 (fr) * 2000-12-27 2002-07-25 Richard T. Wyatt Proteoliposomes immunogenes et applications de ceux-ci
CA2441287C (fr) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cyanovirines resistant a la glycosylation et conjugues, compositions, acides nucleiques, vecteurs, cellules hotes, associes, et procedes d'obtention et d'utilisation des cyanovirines non glycosylees
JP2006504435A (ja) * 2002-05-10 2006-02-09 ザ ヘンリー エム． ジャクソン ファウンデイション ＨＩＶ−１のｇｐ１２０のｇｐ４１への相互作用部位
JP3849584B2 (ja) * 2002-06-07 2006-11-22 トヨタ自動車株式会社 蒸発燃料処理装置
WO2004110384A2 (fr) * 2003-06-12 2004-12-23 Vaxgen, Inc. Glycoproteines d'enveloppe du vih-1 a structure disulfure inhabituelle
CA2539452C (fr) * 2003-09-17 2013-10-29 Guava Technologies, Inc. Compositions et procedes pour l'analyse d'analytes cibles
EP2025762A3 (fr) 2006-01-17 2009-09-30 Health Research Inc. Analyse de suivi hétéroduplex
WO2009010733A2 (fr) * 2007-07-15 2009-01-22 Zealand Pharma A/S Modulateurs peptidiques des jonctions lacunaires
CN107141353A (zh) 2009-03-05 2017-09-08 哈佛学院董事会 分泌的aP2及其抑制方法
WO2011119920A2 (fr) 2010-03-25 2011-09-29 Oregon Health & Science University Glycoprotéines du cmv et vecteurs recombinés
EP2492279A1 (fr) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Procédé de sélection rapide d'immunogène par expression à la surface du lentivirus.
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
EP2568289A3 (fr) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunosélection du virus de la stomatite vésiculaire recombinant exprimant les protéines du VIH-1 par des anticorps largement neutralisants
CA2850745C (fr) 2011-10-03 2022-12-13 Duke University Vaccin
EP2586461A1 (fr) 2011-10-27 2013-05-01 Christopher L. Parks Particules virales dérivées d'un virus enveloppé
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (fr) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Procédés d'identification de nouveaux immunogènes du VIH-1
EP2873423B1 (fr) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Trimères de glycoprotéines d'enveloppe du vih -1 soluble
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3288584A2 (fr) 2015-04-30 2018-03-07 President and Fellows of Harvard College Anticorps anti-ap2 et agents de liaison à l'antigène utilisables en vue du traitement d'affections métaboliques
CA3066733A1 (fr) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Procede d'identification de composes utiles pour traiter une lipogenese deregulee, le diabete et autres troubles apparentes
MX2021009020A (es) * 2019-01-28 2021-09-28 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2102347T3 (es) * 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV

Also Published As

Publication number Publication date
ATE175446T1 (de) 1999-01-15
US5858366A (en) 1999-01-12
WO1991017764A1 (fr) 1991-11-28
US5817316A (en) 1998-10-06
JPH05507491A (ja) 1993-10-28
EP0651818A1 (fr) 1995-05-10
CA2082948C (fr) 2000-07-11
EP0651818A4 (fr) 1993-08-09
DE69130741D1 (de) 1999-02-18
EP0651818B1 (fr) 1999-01-07
DE69130741T2 (de) 1999-07-29

Similar Documents

Publication Publication Date Title
DE69130741D1 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung
CA2164818A1 (fr) Peptides synthetiques en tandem, vaccins contre le vih-1
EP0339504A3 (fr) Virus d'immunodéficience humaine (HIV) peptide env-codé capable de provoquer les anticorps inhibiteurs du HIV dans les mammifères
EP0724651A4 (fr) Anticorps monoclonaux humains synthetiques diriges contre et neutralisant le virus de l'immunodeficience
CA2143163A1 (fr) Peptides derives d'un retrovirus du groupe vih et leur utilisation
WO1993018054A3 (fr) Procede de determination de peptides correspondant a des epitopes importants d'un point de vue immunologique, et leur utilisation dans un procede de determination d'anticorps ou de peptides biotinyles correspondant a ces epitopes, procede pour leur preparation et compositions les contenant
EP0554401A4 (en) Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
AP9801392A0 (en) Concentrated antibody preparation.
CA2046904A1 (fr) Anticorps recombinants propres aux lymphocytes cd4
CA2312004A1 (fr) Preparation specifique a un site de conjugues de polyethylene glycol-grf
WO2002020554A3 (fr) Peptides vih, antigenes, compositions de vaccin, coffret de dosage immunologique et procede permettant la detection d'anticorps induits par vih
ZA200107072B (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV.
DE69632815D1 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
IL95824A0 (en) Peptides associated with cd4 binding region of gp120 and their use
CA2258494A1 (fr) Olypeptides capables de former des structures de liaison a l'antigene avec une specificite pour les antigenes de rhesus d, adn les codant et procede pour leur preparation et leur utilisation
EP0284587A3 (fr) Antigènes peptides synthétiques pour la détection d'infections de HIV-1
CA2091263A1 (fr) Peptides utilises pour la vaccination et l'induction d'anticorps neutralisants contre le virus de l'immunodeficience humaine
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
EP0344006A3 (fr) Peptides bloquant la liaison de HIV-1 vers CD4 du récepteur de protéine
CA2129747A1 (fr) Peptide pour diagnostiquer l'infection a t. cruzi et pour immuniser contre cet agent
CA2052713A1 (fr) Presentation d'agents
WO1991015512A3 (fr) Polypeptides d'enveloppe du vih
EP0306219A3 (fr) Protéines et peptides du HIV pour le diagnostic, la prophylaxie et la thérapie du SIDA
CA2181590A1 (fr) Peptomeres a immunogenicite accrue
EP0478689A4 (en) Human monoclonal antibodies to hiv-1 mn? gp 120

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed